Arrowstreet Capital Limited Partnership Has $58.79 Million Stock Holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Arrowstreet Capital Limited Partnership grew its position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 6.5% during the 4th quarter, according to the company in its most recent filing with the SEC. The firm owned 142,192 shares of the company's stock after purchasing an additional 8,617 shares during the quarter. Arrowstreet Capital Limited Partnership owned 0.17% of IDEXX Laboratories worth $58,788,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors also recently modified their holdings of IDXX. Norges Bank acquired a new position in IDEXX Laboratories in the fourth quarter worth approximately $412,258,000. Flossbach Von Storch SE boosted its stake in shares of IDEXX Laboratories by 5,439.3% during the 4th quarter. Flossbach Von Storch SE now owns 473,336 shares of the company's stock worth $195,696,000 after acquiring an additional 464,791 shares in the last quarter. William Blair Investment Management LLC grew its holdings in shares of IDEXX Laboratories by 701.6% in the 4th quarter. William Blair Investment Management LLC now owns 422,133 shares of the company's stock worth $174,527,000 after acquiring an additional 369,471 shares during the last quarter. Assenagon Asset Management S.A. raised its position in shares of IDEXX Laboratories by 265.6% during the fourth quarter. Assenagon Asset Management S.A. now owns 435,049 shares of the company's stock worth $179,867,000 after purchasing an additional 316,048 shares during the period. Finally, Seilern Investment Management Ltd purchased a new stake in shares of IDEXX Laboratories during the fourth quarter valued at $113,104,000. Institutional investors own 87.84% of the company's stock.

Remove Ads

Insider Activity at IDEXX Laboratories

In other news, Director M Anne Szostak sold 3,000 shares of IDEXX Laboratories stock in a transaction that occurred on Friday, February 7th. The shares were sold at an average price of $465.94, for a total value of $1,397,820.00. Following the completion of the transaction, the director now owns 3,061 shares in the company, valued at approximately $1,426,242.34. The trade was a 49.50 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, EVP George Fennell sold 9,986 shares of the business's stock in a transaction that occurred on Monday, February 10th. The stock was sold at an average price of $462.53, for a total value of $4,618,824.58. Following the completion of the transaction, the executive vice president now directly owns 8,176 shares in the company, valued at $3,781,645.28. The trade was a 54.98 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 2.11% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

A number of brokerages have recently weighed in on IDXX. Barclays lifted their price target on IDEXX Laboratories from $481.00 to $520.00 and gave the company an "overweight" rating in a report on Tuesday, February 4th. Bank of America raised their target price on IDEXX Laboratories from $475.00 to $535.00 and gave the company a "neutral" rating in a report on Tuesday, February 4th. StockNews.com lowered IDEXX Laboratories from a "buy" rating to a "hold" rating in a report on Tuesday, March 25th. Morgan Stanley reduced their target price on IDEXX Laboratories from $559.00 to $550.00 and set an "overweight" rating for the company in a report on Wednesday, January 29th. Finally, Piper Sandler increased their price target on IDEXX Laboratories from $435.00 to $510.00 and gave the company a "neutral" rating in a report on Monday, February 10th. Four research analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average price target of $533.75.

IDEXX Laboratories Price Performance

Shares of NASDAQ:IDXX traded down $17.03 on Friday, hitting $393.73. The stock had a trading volume of 1,635,645 shares, compared to its average volume of 591,359. The firm's 50 day moving average price is $436.39 and its 200-day moving average price is $441.13. The company has a debt-to-equity ratio of 0.28, a quick ratio of 0.95 and a current ratio of 1.31. IDEXX Laboratories, Inc. has a twelve month low of $390.11 and a twelve month high of $548.88. The company has a market capitalization of $31.91 billion, a price-to-earnings ratio of 36.90, a price-to-earnings-growth ratio of 3.41 and a beta of 1.39.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.